We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nanogen Obtains GSA Contract for NanoChip® 400 Platform
News

Nanogen Obtains GSA Contract for NanoChip® 400 Platform

Nanogen Obtains GSA Contract for NanoChip® 400 Platform
News

Nanogen Obtains GSA Contract for NanoChip® 400 Platform

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nanogen Obtains GSA Contract for NanoChip® 400 Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nanogen, Inc. has announced that it has obtained a United States Government Service Administration (GSA) Schedule contract. The contract, number GS-07F-0283T, applies to the company’s NanoChip® 400 microarray instrument and reagents.

The contract enables Nanogen to be listed on an approved GSA Schedule and sell its NanoChip products directly to government agencies such as the National Institutes o f Health (NIH), military hospitals and Veteran’s Administration (VA) hospitals.

Nanogen’s inclusion as a GSA Schedule Vendor allows government customers to obtain approved pricing and license terms from a pre-qualified vendor. Government agencies typically have separate GSA and non-GSA budgets, and therefore inclusion as a GSA vendor allows Nanogen broader access to government customers’ budgets.

“Securing a GSA Schedule contract for the NanoChip platform is a terrific opportunity for Nanogen, because both current and new customers will be able to expedite future purchases through the GSA ordering process,” said David Ludvigson, Nanogen’s president and chief operating officer. “Increased efficiency, coupled with the opportunity for immediate implementation, will be the result for customers in the government sector.”

The NanoChip® 400 instrument is an automated multiplexing platform that laboratories use to detect genetic sequences. Tests can be performed using reagents supplied by Nanogen, or laboratories can develop a variety of “homebrew” assays.

The NanoChip instrument employs Nanogen’s core microarray technology, which utilizes patented microfluidics and electronic technology to automate sample handling and detection of results.

Advertisement